Abstract:Author summary Despite a wealth of information on the epitopes, ontogeny, structure and maturation pathways of multiple epitope classes of HIV-1 broadly neutralizing antibodies (bnAbs), there has been little progress eliciting similar antibodies by vaccination. One major contributing factor is the failure of many candidate immunogens to engage germline reverted forms of bnAbs, making it unlikely that they will provide adequate stimulation of appropriate naive B cells to initiate bnAb lineages. Here we used virus neutralization to identify two point mutations and a modified glycan profile that together render HIV-1 CH505 Env-pseudotyped virus highly susceptible to neutralization by a germline-reverted form of the CH235 lineage of CD4 binding site (CD4bs) bnAbs. These same modifications permit strong binding of corresponding soluble native-like CH505 Env trimers to germline-reverted CH235. These observations provide a conceptual framework for the design and testing of novel immunogens that aim to elicit the CH235 bnAb lineage. The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages of broadly neutralizing antibodies (bnAbs) that are attractive to elicit with vaccines. The CH235 lineage (VH1-46) of CD4bs bnAbs is particularly attractive because the most mature members neutralize 90% of circulating strains, do not possess long HCDR3 regions, and do not contain insertions and deletions that may be difficult to induce. We used virus neutralization to measure the interaction of CH235 unmutated common ancestor (CH235 UCA) with functional Env trimers on infectious virions to guide immunogen design for this bnAb lineage. Two Env mutations were identified, one in loop D (N279K) and another in V5 (G458Y), that acted synergistically to render autologous CH505 transmitted/founder virus susceptible to neutralization by CH235 UCA. Man(5)-enriched N-glycans provided additional synergy for neutralization. CH235 UCA bound with nanomolar affinity to corresponding soluble native-like Env trimers as candidate immunogens. A cryo-EM structure of CH235 UCA bound to Man(5)-enriched CH505.N279K.G458Y.SOSIP.664 revealed interactions of the antibody light chain complementarity determining region 3 (CDR L3) with the engineered Env loops D and V5. These results demonstrate that virus neutralization can directly inform vaccine design and suggest a germline targeting and reverse engineering strategy to initiate and mature the CH235 bnAb lineage.

Staged Induction of HIV-1 Glycan–dependent Broadly Neutralizing Antibodies

Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies Against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.

Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Recognition Of Synthetic Glycopeptides By Hiv-1 Broadly Neutralizing Antibodies And Their Unmutated Ancestors

Initiation of HIV Neutralizing B Cell Lineages with Sequential Envelope Immunizations

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Initiation of Immune Tolerance–controlled HIV Gp41 Neutralizing B Cell Lineages

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancester of CH235 lineage CD4bs broadly neutralizing antibodies.

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Potent and Broad HIV-neutralizing Antibodies in Memory B Cells and Plasma

Augmenting Neutralization Breadth Against Diverse HIV-1 by Increasing the Ab-Ag Interface on V2

Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

Vaccination induces HIV broadly neutralizing antibody precursors in humans

E108 Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation